FY26-27 Adult Covid-19 Vaccines

The Centers for Disease Control and Prevention (CDC) awards one or more Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts for the purchase of standard commercial adult vaccines. 

Vaccines are one of the most cost-effective ways to prevent disease and reduce healthcare costs. The establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial marketplace. These funds provide vaccines for state and local health departments to use in populations at greatest risk for under vaccination and disease.  The 317 program, as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate immunization by partnering with healthcare providers in the public and private sectors.  The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage.  The vaccines awarded under these contracts will be purchased for the National Center for Immunization and Respiratory Disease’s (NCIRD’s) immunization awardees (the fifty state health departments, several large city programs, and current and former U.S. Territories) to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act.  In addition, awardees may opt to purchase additional quantities of vaccine for adults under any resulting contract using state and local funds.

While the primary intention for the contracts is to procure vaccines for the 2026-2027 season, the government also has a requirement to be able to purchase vaccines for the 2025-2026 season, before vaccine becomes available for the 2026-2027 season.